[
  {
    "query": "How much revenue does Microsoft generate from contracts with customers?",
    "golden_answer": "Revenue allocated to remaining performance obligations, which includes unearned revenue and amounts that will be invoiced and recognized as revenue in future periods, was $229 billion as of June 30, 2023, of which $224 billion is related to the commercial portion of revenue. We expect to recognize approximately 45% of this revenue over the next 12 months and the remainder thereafter."
  },
  {
    "query": "When did Coupang's Farfetch consolidation start?",
    "golden_answer": "As announced on January 31, 2024, the acquisition was completed. At closing, the limited partnership provided additional cash funding to Farfetch of $150 million. Additionally, $150 million previously provided under the bridge loan was contributed towards the Farfetch Acquisition. The limited partnership is further obligated to fund Farfetch up to $200 million within twelve months of the acquisition date."
  },
  {
    "query": "What is CPNG's free cash flow?",
    "golden_answer": "Key Financial and Operating Highlights: (in millions)####2023######2022####% Change## Total net revenues##$##24,383####$##20,583####18##% Total net revenues, constant currency(1)##$##24,637####$##23,236####20##% Gross profit(2)##$##6,190####$##4,710####31##% Net income (loss)##$##1,360####$##(92)####NM(3)## Net income (loss) margin####5.6##%####(0.4)##%#### Adjusted EBITDA(1)##$##1,074####$##381####182##% Adjusted EBITDA margin(1)####4.4##%####1.9##%#### Net cash provided by operating activities##$##2,652####$##565####NM(3)## Free cash flow(1)##$##1,775####$##(246)####NM(3)## Segment adjusted EBITDA:################ Product Commerce##$##1,540####$##606####154##% Developing Offerings##$##(466)####$##(225)####107##%"
  },
  {
    "query": "Did abiomed outperform the nasdaq medical equipment index?",
    "golden_answer": "performance graph the following graph compares the yearly change in the cumulative total stockholder return for our last five full fiscal years, based upon the market price of our common stock, with the cumulative total return on a nasdaq composite index (u.s. companies) and a peer group, the nasdaq medical equipment-sic code 3840-3849 index, which is comprised of medical equipment companies, for that period. the performance graph assumes the investment of $ 100 on march 31, 2007 in our common stock, the nasdaq composite index (u.s. companies) and the peer group index, and the reinvestment of any and all dividends.\n\n|                                             | 3/31/2007 | 3/31/2008 | 3/31/2009 | 3/31/2010 | 3/31/2011 | 3/31/2012 |\n| ------------------------------------------- | --------: | --------: | --------: | --------: | --------: | --------: |\n| abiomed inc                                 |       100 |     96.19 |     35.87 |     75.55 |    106.37 |    162.45 |\n| nasdaq composite index                      |       100 |     94.11 |     63.12 |     99.02 |    114.84 |    127.66 |\n| nasdaq medical equipment sic code 3840-3849 |       100 |     82.91 |     41.56 |     77.93 |     94.54 |     74.40 |\n\nthis graph is not \"soliciting material\" under regulation 14a or 14c of the rules promulgated under the securities exchange act of 1934, is not deemed filed with the securities and exchange commission and is not to be incorporated by reference in any of our filings under the securities act of 1933, as amended, or the exchange act whether made before or after the date hereof and irrespective of any general incorporation language in any such filing."
  },
  {
    "query": "What was the change in total expense net of tax for share based compensation from 2014 to 2015 in millions?",
    "golden_answer": "zimmer biomet holdings , inc .\n2015 form 10-k annual report notes to consolidated financial statements ( continued ) these unaudited pro forma results have been prepared for comparative purposes only and include adjustments such as inventory step-up , amortization of acquired intangible assets and interest expense on debt incurred to finance the merger .\nmaterial , nonrecurring pro forma adjustments directly attributable to the biomet merger include : 2022 the $ 90.4 million of merger compensation expense for unvested lvb stock options and lvb stock-based awards was removed from net earnings for the year ended december 31 , 2015 and recognized as an expense in the year ended december 31 , 2014 .\n2022 the $ 73.0 million of retention plan expense was removed from net earnings for the year ended december 31 , 2015 and recognized as an expense in the year ended december 31 , 2014 .\n2022 transaction costs of $ 17.7 million was removed from net earnings for the year ended december 31 , 2015 and recognized as an expense in the year ended december 31 , other acquisitions we made a number of business acquisitions during the years 2014 and 2013 .\nin october 2014 , we acquired etex holdings , inc . ( 201cetex 201d ) .\nthe etex acquisition enhanced our biologics portfolio through the addition of etex 2019s bone void filler products .\nin may 2013 , we acquired the business assets of knee creations , llc ( 201cknee creations 201d ) .\nthe knee creations acquisition enhanced our product portfolio of joint preservation solutions .\nin june 2013 , we acquired normed medizin-technik gmbh ( 201cnormed 201d ) .\nthe normed acquisition strengthened our extremities and trauma product portfolios and brought new product development capabilities in the foot and ankle and hand and wrist markets .\nthe results of operations of these acquired companies have been included in our consolidated results of operations subsequent to the transaction dates , and the respective assets and liabilities of the acquired companies have been recorded at their estimated fair values in our consolidated statement of financial position as of the transaction dates , with any excess purchase price being recorded as goodwill .\nshare-based compensation our share-based payments primarily consist of stock options and restricted stock units ( rsus ).\nshare-based compensation expense was as follows ( in millions ) : .\n\n| for the years ended december 31, | 2015 | 2014 | 2013 |\n| -------------------------------- | ---- | ---- | ---- |\n| total expense pre-tax | $46.4 | $49.4 | $48.5 |\n| tax benefit related to awards | -14.5 (14.5) | -15.5 (15.5) | -15.6 (15.6) |\n| total expense net of tax | $31.9 | $33.9 | $32.9 |"
  },
  {
    "query": "What was the difference in percentage cumulative total shareholder return on masco common stock versus the s&p 500 index for the five year period ended 2017?",
    "golden_answer": "performance graph the table below compares the cumulative total shareholder return on our common stock with the cumulative total return of ( i ) the standard & poor's 500 composite stock index ( \"s&p 500 index\" ) , ( ii ) the standard & poor's industrials index ( \"s&p industrials index\" ) and ( iii ) the standard & poor's consumer durables & apparel index ( \"s&p consumer durables & apparel index\" ) , from december 31 , 2012 through december 31 , 2017 , when the closing price of our common stock was $ 43.94 .\nthe graph assumes investments of $ 100 on december 31 , 2012 in our common stock and in each of the three indices and the reinvestment of dividends .\nthe table below sets forth the value , as of december 31 for each of the years indicated , of a $ 100 investment made on december 31 , 2012 in each of our common stock , the s&p 500 index , the s&p industrials index and the s&p consumer durables & apparel index and includes the reinvestment of dividends. .\n\n| 2013 | 2014 | 2015 | 2016 | 2017 |\n| -------- | -------- | -------- | -------- | -------- |\n| masco | $138.48 | $155.26 | $200.79 | $227.08 | $318.46 |\n| s&p 500 index | $132.04 | $149.89 | $151.94 | $169.82 | $206.49 |\n| s&p industrials index | $140.18 | $153.73 | $149.83 | $177.65 | $214.55 |\n| s&p consumer durables & apparel index | $135.84 | $148.31 | $147.23 | $138.82 | $164.39 |"
  },
  {
    "query": "What is the growth rate in the balance of standby letters of credit from 2006 to 2007?",
    "golden_answer": "the goldman sachs group , inc . and subsidiaries notes to consolidated financial statements the firm is unable to develop an estimate of the maximum payout under these guarantees and indemnifications . however , management believes that it is unlikely the firm will have to make any material payments under these arrangements , and no material liabilities related to these guarantees and indemnifications have been recognized in the consolidated statements of financial condition as of both december 2017 and december 2016 . ... (原文保留)"
  },
  {
    "query": "What is the percentage change in revenue generated from non-us currencies from 2015 to 2016?",
    "golden_answer": "in september 2015 , the company entered into treasury lock hedges with a total notional amount of $ 1.0 billion , reducing the risk of changes in the benchmark index component of the 10-year treasury yield . ... (原文保留)"
  },
  {
    "query": "Show me Apple's revenue growth rate for the last 5 quarters and compare it with industry averages.",
    "golden_answer": "Apple’s revenue grew 8.2% over the past five quarters, outperforming the industry average of approximately 5% driven by continued strength in Services and iPhone segments."
  },
  {
    "query": "Find recent mergers and acquisitions activity in the pharmaceutical industry exceeding $1 billion.",
    "golden_answer": "Major transactions include Pfizer’s $43 billion acquisition of Seagen, Amgen’s $28 billion acquisition of Horizon Therapeutics, and Merck’s $11 billion acquisition of Prometheus Biosciences."
  }
]
